Polynovo Limited PNV

PolyNovo CEO Bruce Peatey talked with Proactive at the ASX Small and Mid-Cap Conference about its proprietary NovoSorb® polymer, the performance of the company, addressable market and what’s next for the company. PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners. The proprietary NovoSorb® polymer is addressing significant unmet needs in woun

The Australian market is experiencing a potential rebound, buoyed by positive developments on Wall Street and a decline in Brent crude prices. As investors navigate these shifting conditions, the appeal of penny stocks remains noteworthy for those seeking opportunities in smaller or newer companies. While the term "penny stocks" may seem outdated, these investments can still offer surprising value by focusing on companies with robust financials and clear growth trajectories.

As the Australian share market faces a challenging period with consecutive days of declines, investors are keenly observing how global economic pressures and fluctuating commodity prices impact local indices. In this environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests, making them potential standouts in a volatile market.

As the Australian share market faces a challenging period with a seven-day streak of declines, investors are keenly observing opportunities that may arise from these turbulent times. In such an environment, identifying stocks that are trading below their estimated value can be crucial for investors looking to capitalize on potential undervaluation in the market.

In February 2026, PolyNovo Limited reported half-year results for the period to 31 December 2025, with revenue rising to A$74.98 million from A$59.89 million a year earlier, while net income eased to about A$0.003 million from A$3.34 million. This combination of strong top-line growth but sharply compressed profitability highlights how higher sales have not yet translated into meaningful earnings progress for PolyNovo. We’ll now examine how this revenue growth alongside weaker net income...